Avanir Pharmaceuticals, Inc. (Avanir) is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company�s lead product NUEDEXTA (referred to as AVP-923 during clinical development) is a dual NMDA receptor antagonist and sigma-1 agonist. NUEDEXTA, 20/10 milligram, is approved in the United States for the treatment of pseudobulbar affect (PBA). It is also approved for PBA in the European Union. It is studying the clinical utility of AVP-923 in other mood or behavior disorders, movement disorders and pain. It has two ongoing Phase II clinical trials exploring the potential treatment of agitation in patients with Alzheimer�s disease and potential treatment of levodopa-induced dyskinesia in Parkinson�s disease (the LID study). It is also developing a Breath Powered intranasal delivery system containing low-dose sumatriptan powder to treat acute migraine, AVP-825.